Acadia Pharmaceuticals | ACAD - Selling And Administration Expenses

Stock Price
24.13
Daily Change
0.14 0.58%
Monthly
-10.16%
Yearly
23.87%
Q1 Forecast
23.25

Acadia Pharmaceuticals reported $124.9M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 124.9M 1.24M Sep/2025
ALKERMES USD 171.77M 17.9M Sep/2025
Alnylam Pharmaceuticals USD 285.06M 22.47M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
BioMarin Pharmaceutical USD 223.42M 8.86M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Cara Therapeutics USD 4.64M 2.19M Mar/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Cytokinetics USD 158.75M 93.03M Sep/2025
Eisai JPY 111.72B 7.86B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Incyte USD 390.41M 61.33M Dec/2025
J&J USD 6.75B 831M Dec/2025
Moderna USD 308M 40M Dec/2025
Neurocrine Biosciences USD 301.8M 10.2M Dec/2025
Pfizer USD 4.08B 894M Dec/2025
Prothena USD 13.24M 2.67M Sep/2025
PTC Therapeutics USD 87.2M 3.15M Dec/2025
Sarepta Therapeutics USD 77.11M 7.22M Sep/2025
Ultragenyx Pharmaceutical USD 89M 2.38M Dec/2025
Vanda Pharmaceuticals USD 39.28M 1.71M Dec/2024
Vertex Pharmaceuticals USD 487M 41.9M Dec/2025